Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALASCCA: Low Dose Aspirin in Colorectal Cancer Patients With PI3K Pathway Mutations
NCT02647099Phase 3Active, not recruiting
- Start
- Apr 2016
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing Aspirin with Placebo (2 arms). Primary endpoint: Time To Recurrence at 3 years. Started Apr 2016; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02647099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647099.